Business Context and Reporting Period
Company: Sunshine Biopharma Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2018
Event: Entry into a Material Definitive Agreement with GHS Investments LLC.
Key Financial Metrics and Transaction Terms
- Financing Capacity: Up to $10,000,000 in equity financing contingent upon the effectiveness of a Form S-1 Registration Statement.
- Transaction Structure: The Company has the discretion to deliver "puts" to GHS, obligating GHS to purchase common stock.
- Put Limitations:
- Maximum per notice: The lesser of 250% of the average daily trading volume (10-day) or $300,000.
- Ownership Cap: GHS beneficial ownership cannot exceed 9.99% of outstanding common stock.
- Price: 81% of the Market Price.
- Duration: Puts may be delivered until the earlier of 36 months after Registration Statement effectiveness or the full $10,000,000 is purchased.
- Debt Instrument: A promissory note issued to GHS for $20,000 to offset transaction costs.
- Interest Rate: 8% per annum.
- Maturity Date: June 30, 2019.
- Convertible: No.
Material Changes and Registration Rights
The filing discloses a new financing arrangement rather than a change in historical financial performance. Key obligations include:
- Registration Timeline: The Company must file the Registration Statement within 30 days of the agreement date.
- Effectiveness Deadline: The Registration Statement must be declared effective within 30 days of filing, but no later than 90 days after filing.
Guidance, Outlook, and Risks
Outlook: The agreement is designed to provide capital flexibility through a put mechanism, subject to market liquidity (trading volume) and regulatory approval (S-1 effectiveness).
Risks and Contingencies:
- Regulatory Risk: The $10,000,000 funding is contingent on the SEC declaring the S-1 Registration Statement effective.
- Liquidity Risk: The ability to raise funds via puts is capped by the company's average daily trading volume, limiting the speed of capital deployment.
- Dilution: Issuance of shares at 81% of market price will result in dilution to existing shareholders.
Unusual Items: The filing does not report unusual items outside of the standard terms of the equity financing agreement.
Investor Verification Checklist
- Verify the filing status and expected effectiveness date of the Form S-1 Registration Statement.
- Review the company's recent average daily trading volume to assess the practical limit on immediate capital raises ($300,000 cap vs. volume cap).
- Confirm the current beneficial ownership percentage of GHS Investments LLC to understand the remaining capacity before hitting the 9.99% cap.
- Monitor the company's cash position relative to the $20,000 promissory note due June 30, 2019.